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INTRODUCTION {#s1}
============

Guillain-Barré syndrome (GBS) is an acute monophasic immune-mediated polyradiculoneuropathy.^[@R1]^ However its precise molecular pathogenesis and variants are uncertain.^[@R2]^ Although GBS may occur among all ages, its mean age of onset is reported differently. It affects male slightly more than female patients.^[@R1],[@R3],[@R4]^ Also, the worldwide incidence of GBS varies broadly.^[@R5],[@R6]^ The overall incidence of GBS in children is lower than adults.^[@R7]^ There are several types of GB including acute inflammatory demyelinating polyradiculoneuropathy (AIDP); axonal forms of GBS, such as acute motor-sensory axonal neuropathy (AMSAN) and acute motor axonal neuropathy (AMAN); and miller fisher syndrome (MFS), which has been reported that there is a possible association between MFS, thromboembolic disease, and angioedema.^[@R8]-[@R10]^ In addition, one of its rare variant consists of facial diplegia and paresthesia, which can make the diagnosis difficult.^[@R11]^ Although autonomic dysfunction is a known but rare presentation of GBS that should be considered in the differential diagnosis in patients with refractory bradycardia and hypotension,^[@R12]^ it is stated to be preceded by a non-specific infection of variable type, usually a few weeks before the onset of neurological symptoms. Meanwhile trauma, surgery, or vaccination would be as triggering factors.^[@R13]^ Here, we report a case of a young man with AMAN subtype of GBS having hepatitis A virus (HAV) infection.

CASE REPORT {#s2}
===========

A 30-year-old man with icterus was referred to emergency center of Razi Hospital. There was no history of disease, smoking, or drug abuse. He stated to have flu-like symptoms 10 days before the onset of icterus, which was treated as an outpatient. Also, he suffered from gradual fatigue and weakness with dark urine. Then he was referred to the Department of Gastrointestinal and Liver Diseases of Razi Hospital for admission. In addition, the patient declared nausea, fever, and chills, which had improved over the previous 2 days, while the icterus still remained. There was no history of disease among him and his family. He reported a history of appendectomy 15 years earlier. His initial blood test showed high levels of liver function enzymes, hyperbilirubinemia as well as high C-reactive protein (CRP) ([table1](#T1){ref-type="table"}). Also, [table 2](#T2){ref-type="table"} shows the results of urine analysis.

###### Blood test report

  ---------------------------------------------------------------------- ------------------------------------------------------------------
  White blood cell (WBC): 7.3×103/UL (4-10 ×103/UL)                      Creatinine (Cr): 0.78 (0.8-1.3 mg/dL)
  Hemoglobin (HB): 15.4 (13-17.5 g/dL )                                  Blood urea nitrogen (BUN): 16 (7-20 mg/dL)
  Mean corpuscular volume (MCV): 85.2 (80-100 FL)                        Estimated glomerular filtration rate (eGFR): 87 (\> 60 nmol/24h)
  Mean corpuscular hemoglobin concentration (MCHC): 33.7 (31-37 gr/dL)   Total protein (Total Pr): 8 (6.6-8.8 gr/dL)
  Platelet (PLT): 245×103/UL (150-450 ×103/UL)                           Lipase: 34 (0-160 U/L)
  Ferritin: 610 (12-300 ng/mL)                                           Lactate dehydrogenase (LDH): 341 (100-190 U/L)
  Albumin (Alb): 4.5 (3.5-5 g/dL)                                        Bilirubin total (Bill T): 27 (0-1.1 mg/dL)
  Potassium (K): 4 (3.5-5.3 mEg/L)                                       Bilirubin direct (Bill D): 16.4 (0-0.7 mg/dL)
  Sodium (Na): 134 (135-145 mEg/L)                                       Aspartate aminotransferase (AST): 628 (\< 40 IU/L)
  Calcium (Ca): 9.6 (8.5-10.5 mg/dL)                                     alanine aminotransferase (ALT): 127 (\< 40 IU/L )
  Phosphorus (P): 3.2 (2.5-4.5 mg/dL)                                    Alkaline Phosphatase (Alk p): 298 (64-306 IU/L)
  Magnesium (Mg): 2.5 (1.7- 2.2 mg/dL)                                   Creatine phosphokinase (CPK): 36 (24-195 U/L)
  Erythrocyte sedimentation rate (ESR): 21 (0-22 mm/hr)                  Iron (Fe): 64 (13.5-17.5 g/dL)
  C-reactive protein (CRP): 14 (\< 6 mg/L)                               Total iron-binding capacity (TIBC): 131 (240-450 mcg/dL)
  ---------------------------------------------------------------------- ------------------------------------------------------------------

###### The urine analysis

  ----------------------------- ----------------------
  ketone: negative              bilirubin: negative
  blood: negative               urobilinogen: 1+
  White blood cell (WBC): 2-3   color: orange
  RED blood cell (RBC): 1-2     appearance: clear
  bacteria: rare                PH: 6.8
  nitrite: negative             urine protein: trace
  crystal ca-oxalate: many      Glucose: negative
  ----------------------------- ----------------------

On the second day of admission, he experienced neurological symptoms of muscle paralysis (ascending from the legs to hands). Neurological consultant suspected GBS based on clinical examinations. The patient was scheduled for five sessions of plasmapheresis for the first step because in any situations of GBS suspicion, treatment is vital.

According to the imaging evaluations such as ultrasonography, the liver span was 166 mm, which was greater than the normal range, with normal parenchymal echo. Intra- and extrahepatic bile ducts were normal. The gallbladder wall was thicker than normal and gallstone with lesion was not seen in different locations.

The specific viral marker tests were ordered due to acute hepatitis (viral or autoimmune) symptoms which showed: hepatitis B surface antigen (HBS Ag): negative, hepatitis C virus antibody (HCV Ab): negative, epstein-barr virus (EBV) (viral capsid antigen (VCA) \[immunoglobulin M (IgM):-, immunoglobulin G (IgG):+\]), cytomegalovirus (CMV): negative, herpes simplex virus (HSV) (IgG): positive, serum HAV (IgM): positive, anti hepatitis E virus(HEV)( IgM): negative, anti HEV (IgG): negative, gamma: 1.7 (0.6-1.5 g/dL), beta: 0.9 (0.5-1.2 g/dL), alpha2: 0.8 (0.6-1.1 g/dL), alpha 1: 0.3 (0.1-0.2 g/dL), albumin: 3.8 (3.2-5.3 g/dL) with detection of IgM & Kappon & lambdco light chains bands in serum immune fixation report. Antinuclear antibody (ANA): negative, anti-smooth muscle antibody (ASMA): negative.

In addition, during neurological consultation, the suspicion to GBS and vasculitis led to proper further laboratory tests, which showed the following results: anti-double stranded DNA (anti-dsDNA): 3.2 (\< 25 U/mL), C. Proteinase 3 (PR3) anti-neutrophil cytoplasmic antibody (ANCA) (PR3-ANCA): \< 3 (\< 12 Au/mL), Perinuclear ANCA (P- ANCA) \[anti- myeloperoxidase (anti MPO)\]: 3.7 (\< 12 Au/mL), anti-mitochondrial Ab (AMA): negative, lupus anticoagulant (LAC): negative and, anti-liver-kidney-microsome antibody (LKMA): 3.1(\< 12 Au/mL).

These findings made the possibility of GBS stronger rather vasculitis. After completion of plasmapheresis sessions, the neurological abilities and muscular power of the patient improved completely. Also, the diagnosis of AMAN subtype of GBS was confirmed based on the electromyogram (EMG)/nerve conduction velocity (NCV) findings, which were performed during the plasmapheresis ([table 3](#T3){ref-type="table"}). The patient was discharged from the Gastroenterology and Neurology Department. After 2-month follow-up, the results of International normalized ratio (INR), partial thromboplastin time (PTT), prothrombin time (PT), alkaline phosphatase (ALK), alanine aminotransferase (ALT) , aspartate aminotransferase (AST), bilirubin total and direct (Bil T, D) tests were normal.

###### The EMG and NCV findings that are compatible with mild acute motor axonal neuropathy

  ------------------------------ ---------- ----------------- ---------------- -------------------- ------------------------ -------- -------- ------
  **NERVE CONDUCTION STUDIES**                                                                                                                 
                                 **AMP.**   **LATENCY**       **NCV**          **F WAVE LATENCY**                                              
  R. MEDIAN MOTOR                4.7        3.2               53               28                                                              
  R. ULNAR MOTOR                 5.4        2.5               55               26                                                              
  L. MEDIAN MOTOR                3.9        3.5               53               25                                                              
  L. ULNAR MOTOR                 4.9        2.9               55.1             26                                                              
  R. MEDIAN SENSORY              22         3.4                                                                                                
  R. ULNAR SENSORY               19         2.7                                                                                                
  L. MEDIAN SENSORY              27         2.8                                                                                                
  L. ULNAR SENSORY               26         3.4                                                                                                
  R. RADICAL SENSORY             12         2.3                                                                                                
  R. SAPHENOUS SENSORY                                                                                                                         
  R. D. PERONEAL. M              2.45       5.23              36               ABSENT                                                          
  R. POS. TIBIAL. M              3.67       5.3               36               ABSENT                                                          
  L. D. PERONEAL. M              2.34       5.7               38               ABSENT                                                          
  L. POS. TIBIAL M               4.3        6.2               35               ABSENT                                                          
  R. S.P.N SENSORY               5.7                                                                                                           
  L. S.P.N SENSORY               4.87                                                                                                          
  R. SURAL. SENSORY              6.7                                                                                                           
  L. SURAL. SENSORY              5.9                                                                                                           
  R. H REFLEX                    33                                                                                                            
  L. H REFLEX                    34                                                                                                            
  **EMG**                                                                                                                                      
  **MUSCLE**                     **ROOT**   **INSER. ACT.**   **FIB. P.SW**    **FASCI**            **VOLUNTARY M.U.A.Ps**                     
  **dur. recu.pat**              **amp**    **polyph**        **activation**                                                                   
  R. TRICEPS                     C6,7,8     Normal            Normal           Normal               Normal                   Normal   Normal   Full
  L. TRICEPS                     C6,7,8     Normal            Normal           Normal               Normal                   Normal   Normal   Full
  R. EDC                         C7,8       Normal            Normal           Normal               Normal                   Normal   Normal   DEC
  R. FDI                         C8,T1      Normal            Normal           Normal               Normal                   Normal   Normal   full
  R. TIBIALIS ANTERIOR           L4,L5      Normal            Normal           Normal               Normal                   Normal   Normal   DEC
  L. TIBIALIS ANTERIOR           L4,L5      Normal            Normal           Normal               Normal                   Normal   Normal   DEC
  R. PERONEUS LONGUS             L5,S1      Normal            Normal           Normal               Normal                   Normal   Normal   DEC
  L. PERONEUS LONGUS             L5,S1      Normal            Normal           Normal               Normal                   Normal   Normal   DEC
  R. GASTROCNEMIUS                          Normal            Normal           Normal               Normal                   Normal   Normal   DEC
  ------------------------------ ---------- ----------------- ---------------- -------------------- ------------------------ -------- -------- ------

EMG: Electromyography; NCV: Nerve conduction velocity; R: Right; L: Left; AMP: Amplitude; POS: Posterior; D. PERONEAL: Deep Peroneal; S.P.N: Superficial peroneal nerve; INSER.; ACT: Insertion activity; FIB. P.SW: Fibrillation positive sharp wave; FASCI: Fasciculation voluntary; M.U.A.P: Voluntary motor unit action potential; Dur. Recu.pat: Duration recruitment pattern; Polyph: Polyphasic; EDC: Extensor digitorum communis; FDI: First dorsal interosseous, EHL: Extensor Hallucis Longus

DISCUSSION {#s3}
==========

Viral hepatitis has rare complications such as GBS, auditory neuritis, seizures, and mononeuritis. The frequent association between GBS and hepatotropic viruses including cytomegalovirus, acute viral hepatitis B (HB), acute hepatitis C, hepatitis D, hepatitis E (HE), and rarely with hepatitis A (HA) has been reported.^[@R14],[@R15]^ Also, several neurological complications are in association with viral HA such as transverse myelitis, myeloradiculopathy, mononeuropathy, and mononeuritis, which have immune pathogenesis bases.^[@R16]^ Furthermore, a variety of neurological syndromes including GBS have been reported in serologically confirmed hepatitis A .^[@R17],[@R18]^ The pathogenesis of HA virus-associated GBS is unknown. It is stated that there should be a molecular resemblance between hepatotropic viruses' antigens such as HA and the components of myelin in the peripheral nerves.^[@R14]^ While it is required to conduct precise epidemiological evaluations to distinguish the relationship between HA viral infection and GBS, it is suggested that this type of infection has a molecular mimicry as shares cross reactive epitopes, which in turn cross reacts with Schwann cells, myelin, or other peripheral nerve antigens.^[@R19]^ However these possibilities require further explorations.^[@R20]^ It has been revealed that GBS following HAV is male dominant, occurs in younger ages, and its overall prognosis is better unlike other infections such as C. Jejuni.^[@R21]^ Meanwhile, there is no relationship between the severity of neurological symptoms and the fulminant hepatitis, which is not common among the patients. The clinical features of GBS following HA is summarized as follows: I) less than 14 days interval between the onset of hepatitis and the development of neuropathic symptoms, II) frequent association with facial nerve palsy, III) frequent impairment of joint position and vibratory sense along with superficial sensation, and IV) appropriate outcome of the neuropathic symptoms, which is independent of ALT level associated with liver dysfunction severity.^[@R22]^ In addition, one of the GBS subtypes characterized by pure motor involvement and absence of evidence of demyelination in electrophysiological tests is AMAN,^[@R23]^ which is linked to Campylobacter jejuni and Zika virus infection based on the available literature.^[@R24],[@R25]^ There is no certain report about the AMAN frequency, which is claimed to be a consequence of variability in infectious agents exposure in different geographical areas. In spite of that, the estimated incidence of AMAN is 30-65% in Asia and Central and South America.^[@R26]^ According to some reports this form of GBS has an incidence from \< 10% of the patients with GBS in Western countries to over 40% in East Asia where it frequently affects.^[@R27]-[@R29]^ It is characterized by rapidly progressive weakness, often with respiratory failure and usually good recovery, in comparison with other subtypes such as AMSAN, which is generally associated with slow and incomplete recovery.^[@R30]^ Regarding electrodiagnostic studies, most of the cases were compatible with an acquired demyelinating polyradiculoneuropathy, while just a few cases had dominant axonal involvement like AMAN.^[@R31],[@R32]^ Also, it has been stated that GBS is vastly connected to HE infection rather than HAV infection.^[@R33]^ In our case, as the patient did not have the risk factors of HE such as journey to Pakistan or other endemic areas, pregnancy, and immunodeficiency but had the risk factors of viral HA and HB infection including flu-like symptoms, fever, and icterus, we did not check HE, while his result was positive for serological HAV IgM. Also, in this case there was no facial palsy that is frequent in this subtype of GBS.

CONCLUSION {#s4}
==========

Remarkably, considering the accurate type of viral hepatitis infection in patients with different subtypes of GBS in the golden time which has an impressive key role in diminishing the neurological symptoms, we should not correlate and consider all the patients' complaints to the liver disease. Meaningly; it must be considered according to other main related disorders. Although, AMAN subtype of GBS is common with HEV infection, the possibility of HAV infection in cases with its risk factor should not be neglected.
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